JSPR

Jasper Therapeutics, Inc.

0.50 USD

Last updated Dec 9, 17:57 UTC

Yesterday HIGH

$0.53

Yesterday LOW

$0.48

52w HIGH

$3.8

52w LOW

$0.39

EPS

-0.16

PE

-3.13

Next Earnings

Mar 6, 2024

Overview News Insider Transactions Government Trades

Jasper Therapeutics, Inc. stock is down -32.27% since 30 days ago. The next earnings date is Mar 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 December’s closed higher than November.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering. The company is based in Redwood City, California.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

www.jaspertherapeutics.com

richadhand@benzinga.com

Mon May 15, 2023

Credit Suisse Reiterates Outperform on Jasper Therapeutics, Maintains $4 Price Target

Credit Suisse analyst Judah Frommer reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and maintains $4 price target.
Benzinga Insights

Fri May 12, 2023

Jasper Therapeutics: Q1 Earnings Insights
Happy Mohamed

Fri May 12, 2023

Jasper Therapeutics Q1 EPS $(0.16), Inline

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.16) per share which met the analyst consensus estimate. This is a 166.67 percent decrease over losses of $(0.06) per share from the same period last
Michael Horton

Fri Apr 28, 2023

Jasper Therapeutics Files For Mixed-Securities Shelf Offering Of Up To $250M

-SEC Filing
Lisa Levin

Wed Apr 12, 2023

$4M Bet On Jasper Therapeutics? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

The Dow Jones closed higher by around 100 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Lisa Levin

Wed Apr 12, 2023

Why iMedia Brands Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket

Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) jumped 119.6% to $1.96 in pre-market trading. HeartCore forged an agreement with rYojbaba Inc for its tenth Go IPO consulting service win.
Benzinga Newsdesk

Thu Mar 9, 2023

EF Hutton Reiterates Buy on Jasper Therapeutics, Maintains $6.85 Price Target

EF Hutton analyst Michael King reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $6.85 price target.
Benzinga Newsdesk

Thu Mar 9, 2023

Cantor Fitzgerald Reiterates Overweight on Jasper Therapeutics, Maintains $6 Price Target

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Overweight and maintains $6 price target.
richadhand@benzinga.com

Thu Mar 9, 2023

Credit Suisse Reiterates Outperform on Jasper Therapeutics, Maintains $4 Price Target

Credit Suisse analyst Judah Frommer reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and maintains $4 price target.
Happy Mohamed

Wed Mar 8, 2023

Jasper Therapeutics Q4 EPS $(0.36), Inline

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.36) per share which met the analyst consensus estimate. This is a 44 percent decrease over losses of $(0.25) per share from the same period last year.

WIGGANS THOMAS G, Director

Tue Nov 28, 2023

JSPR Recent Insider Trades and Stock Chart

10,000 shares bought
WIGGANS THOMAS G, Director

Tue Nov 21, 2023

JSPR Recent Insider Trades and Stock Chart

10,000 shares bought
WIGGANS THOMAS G, Director

Thu Nov 16, 2023

JSPR Recent Insider Trades and Stock Chart

10,000 shares bought
WIGGANS THOMAS G, Director

Fri Nov 17, 2023

JSPR Recent Insider Trades and Stock Chart

10,000 shares bought
WIGGANS THOMAS G, Director

Mon Nov 20, 2023

JSPR Recent Insider Trades and Stock Chart

10,000 shares bought